Welcome to the Head and Neck Surgery Webinar 2025!
Hosted by Globalmeetx
It is our pleasure to welcome you to the Head and Neck Surgery Webinar 2025, a cutting-edge virtual event bringing together surgeons, oncologists, and medical professionals from around the world. This event serves as a hub for sharing pioneering research, advanced surgical techniques, and collaborative approaches to patient care.
Engage in thought-provoking sessions, case-based discussions, and valuable exchanges with leading experts. We’re excited to have you join us in advancing excellence in head and neck surgery.
About the Head and Neck Surgery Webinar
The Head and Neck Surgery Webinar is a premier online event that brings together top-tier surgeons, researchers, and medical professionals committed to advancing care in head and neck surgery. Hosted by Globalmeetx, this platform serves as a nexus for sharing clinical expertise, research breakthroughs, and multidisciplinary approaches to complex cases.
Covering topics such as minimally invasive surgery, oncology, reconstructive procedures, and emerging surgical technologies, the webinar offers deep insights through keynote talks, case studies, and expert panels. Join us to exchange ideas, build professional connections, and stay at the forefront of surgical innovation in head and neck healthcare.
Minimally invasive surgery continues to redefine standards in head and neck procedures. This session will cover recent breakthroughs in endoscopic and transoral techniques, including Transoral Robotic Surgery (TORS) and endoscopic laser microsurgery. Discussions will include case studies highlighting improved cosmetic outcomes, faster recovery, and fewer complications. Emphasis will be placed on indications, contraindications, and patient selection to optimize surgical success.
The fusion of robotics and artificial intelligence has opened new frontiers in precision and safety. This session dives into robotic systems used in tumor resection, reconstructive planning, and remote access procedures. Experts will discuss AI-driven intraoperative guidance, predictive analytics, and machine learning models for diagnostics. Attendees will gain insights into how these technologies are reshaping workflows, surgeon training, and patient outcomes.
Reconstruction after head and neck cancer surgery demands both functional and aesthetic excellence. This track highlights the latest developments in free flap design, composite tissue transfer, and real-time intraoperative vascular monitoring. Attendees will also explore tissue engineering advancements and the integration of digital surgical planning for personalized reconstruction, helping improve patient quality of life post-surgery.
3D printing is transforming preoperative planning and intraoperative precision. This session explores its use in modeling complex anatomy, fabricating patient-specific implants, and enhancing surgeon-patient communication through visual planning. Real-world case presentations will illustrate how 3D technologies improve surgical accuracy, decrease operation time, and reduce intraoperative surprises, especially in craniofacial and mandibular reconstruction.
This session focuses on evolving paradigms in managing advanced cancers while preserving critical functions such as speech, swallowing, and breathing. It will feature updates on chemoradiotherapy protocols, transoral surgical techniques, and imaging modalities that aid in early tumor delineation. Multidisciplinary approaches and decision-making frameworks will be highlighted for achieving optimal balance between survival and quality of life.
The rise in HPV-related oropharyngeal cancers has shifted the clinical landscape. This track examines its distinct pathophysiology, treatment algorithms, and emerging surgical strategies, including the role of TORS in de-intensification protocols. Discussions will include diagnostic advancements, long-term outcomes, and prevention through vaccination, alongside the implications of staging system updates.
Microvascular surgery remains the gold standard for complex reconstructions. This session will spotlight advanced flap harvesting techniques, perforator-based flaps, and innovations in vessel anastomosis. Attendees will also explore strategies for minimizing donor site morbidity and managing high-risk patients, as well as the role of preoperative imaging and perfusion assessment.
Artificial intelligence is revolutionizing diagnostic accuracy and decision support. This session presents current AI applications in radiology, pathology, and electronic medical records to predict disease progression and guide treatment. Case demonstrations will showcase how machine learning is integrated into clinical settings, improving diagnostic speed and enhancing early cancer detection.
This session provides an in-depth look at endoscopic management of complex sinonasal and skull base tumors. Topics include expanded endonasal approaches, image-guided navigation, and hemostatic innovations. Emphasis will be placed on surgical anatomy, complication avoidance, and interdisciplinary collaboration with neurosurgeons and radiologists to ensure comprehensive care.
Advancements in endocrine surgery continue to improve patient safety and aesthetic results. This session will cover innovations such as scarless transoral approaches, intraoperative nerve monitoring, and real-time PTH assessment. Special attention will be given to managing reoperations, high-risk malignancies, and integrating surgical strategies with endocrinology care pathways.
Skull base tumors present unique challenges due to anatomical complexity and proximity to critical neurovascular structures. This session addresses both traditional and endoscopic approaches, reconstruction strategies, and outcomes for benign and malignant lesions. Attendees will learn about advanced imaging, intraoperative navigation, and complication management in high-stakes cases.
This track focuses on coordinated care for advanced-stage cancers, including T4 tumors and recurrent disease. The session will emphasize the role of tumor boards, coordinated surgical and adjuvant treatments, and palliative strategies when appropriate. Case-based discussions will illustrate how collaborative efforts among surgeons, medical oncologists, radiation oncologists, and rehab teams optimize both survival and function.
Our webinars are thoughtfully designed to deliver value to a wide range of individuals. Whether you're looking to grow your skills, explore new opportunities or gain insights from experts, here's who will benefit most from attending:
In a world where knowledge is power, webinars have emerged as one of the most accessible and impactful ways to learn, grow and connect. Don't miss the chance to learn, grow and connect in ways that truly matter.
Registering for a webinar is essential to gain access to the unique opportunities and secure a chance to grow, connect and gain insights that can drive your personal and professional success. Webinars are more than just online meetings, they're gateways to knowledge, innovation, and growth.
Market Analysis:
Head and Neck Cancer refers to several types of cancers that affect the head and neck areas of the body. These cancers account for approximately 3–5% of all cancers in the US and are common in men and people over the age of 50.
As per DelveInsight’s epidemiology model, the total incident cases of Head and Neck Cancer (HNC) in the 7MM was around 162,000 in 2023, and the United States showed the highest incident cases of HNC representing ~41% of total cases in the 7MM.
In 2023, the site-specific incident cases of HNC in the US were maximum for oral and oropharyngeal cancer at nearly 70% cases, followed by laryngeal and hypopharyngeal cancer; nasopharyngeal cancer; salivary gland cancer; and nasal cavity and paranasal sinus cancer.
Many HNC can be cured, especially if diagnosed early. Although eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also important.
Among the 7MM, the United States accounted for the largest market size (more than USD 2,000 million) of head and neck cancer, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan in 2023.
In December 2023, Exelixis announced the initiation of STELLAR-305, a Phase II/III pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
As per DelveInsight’s estimates, the potential drugs that can mark a significant change in the market during the forecast period include Leukocyte Interleukin (CEL-SCI), Zanzalintinib + pembrolizumab (Exelixis), and others.
The current median overall survival for head and neck squamous cell carcinoma (HNSCC) patients in recurrent or metastatic situations is 8 months, underlining the biggest unmet need for additional effective therapies that can increase overall survival for HNSCC patients